Advertisement

European Radiology

, Volume 28, Issue 6, pp 2700–2707 | Cite as

Benefit of 18F-fluorocholine PET imaging in parathyroid surgery

  • G. F. HuberEmail author
  • M. Hüllner
  • C. Schmid
  • A. Brunner
  • B. Sah
  • D. Vetter
  • P. A. Kaufmann
  • G. K. von Schulthess
Nuclear Medicine

Abstract

Objectives

To assess the additional diagnostic value of 18F-fluorocholine PET imaging in preoperative localization of pathologic parathyroid glands in clinically manifest hyperparathyroidism in case of negative or conflicting ultrasound and scintigraphy results.

Methods

A retrospective, single-institution study of 26 patients diagnosed with hyperparathyroidism. In cases where ultrasound and scintigraphy failed to detect the location of an adenoma in order to allow a focused surgical approach, an additional 18F-fluorocholine PET scan was performed and its results were compared with the intraoperative findings.

Results

A total of 26 patients underwent 18F-fluorocholine PET/CT (n = 11) or PET/MRI (n = 15). Adenomas were detected in 25 patients (96.2%). All patients underwent surgery, and the location predicted by PET hybrid imaging was confirmed intraoperatively by frozen section and adequate parathyroid hormone drop after removal. None of the patients needed revision surgery during follow-up.

Conclusions

These results demonstrate that 18F-fluorocholine PET imaging is a highly accurate method to detect parathyroid adenomas even in case of previous localization failure by other imaging examinations.

Key Points

With 18 F-fluorocholine PET imaging, parathyroid adenomas could be detected in 96.2%.

18 F-fluorocholine imaging is a highly accurate method to detect parathyroid adenomas.

We encourage its use, where ultrasound fails to detect an adenoma.

Keywords

Hyperparathyroidism Choline PET/CT PET/MR Minimally invasive surgical procedures 

Notes

Funding

The authors state that this work has not received any funding.

Compliance with ethical standards

FCh-PET in patients with HPT is an approved clinical imaging procedure in our country, and is therefore partly reimbursed by health insurance. Permission for conducting our study was obtained by the ethical committee responsible for our hospital (no. 2016-01616). Due to the retrospective nature of our study, written general informed consent of patients was deemed sufficient by the institutional review board for inclusion into the study. Patients who refused to give signed informed consent were not included into the study. All co-authors mentioned above disclose no potential conflicts of interest.

Guarantor

The scientific guarantor of this publication is Gerhard Huber.

Conflict of interest

The authors of this manuscript declare no relationships with any companies, whose products or services may be related to the subject matter of the article.

Statistics and biometry

No complex statistical methods were necessary for this paper.

Informed consent

Written informed consent was obtained from all subjects (patients) in this study.

Ethical approval

Institutional review board approval was obtained.

Methodology

• prospective

• observational

• performed at one institution

References

  1. 1.
    von Schulthess GK, Weder W, Goebel N et al (1988) 1.5 T MRI, CT, ultrasonography and scintigraphy in hyperparathyroidism. Eur J Radiol 8:157–164Google Scholar
  2. 2.
    Noussios G, Anagnostis P, Natsis K (2012) Ectopic parathyroid glands and their anatomical, clinical and surgical implications. Exp Clin Endocrinol Diabetes 120:604–610CrossRefPubMedGoogle Scholar
  3. 3.
    Randolph G (2002) Surgery of the Thyroid and Parathyroid Glands, 1st edn. WB Saunders Company, PhiladelphiaGoogle Scholar
  4. 4.
    Suh YJ, Choi JY, Kim SJ et al (2015) Comparison of 4D CT, ultrasonography, and 99mTc sestamibi SPECT/CT in localizing single-gland primary hyperparathyroidism. Otolaryngol Head Neck Surg 152:438–443CrossRefPubMedGoogle Scholar
  5. 5.
    Krakauer M, Wieslander B, Myschetzky PS et al (2016) A Prospective Comparative Study of Parathyroid Dual-Phase Scintigraphy, Dual-Isotope Subtraction Scintigraphy, 4D-CT, and Ultrasonography in Primary Hyperparathyroidism. Clin Nucl Med 41:93–100CrossRefPubMedGoogle Scholar
  6. 6.
    Sommerauer M, Graf C, Schäfer N et al (2015) Sensitivity and specificity of Dual-Isotope 99mTc-Tetrofosmin and 123I Sodium Iodide Single Photon Emission Computed Tomography (SPECT) in hyperparathyroidism. PLoS One 10(6):e0129194Google Scholar
  7. 7.
    Nael K, Hur J, Bauer A et al (2015) Dynamic 4D MRI for Characterization of Parathyroid Adenomas: Multiparametric Analysis. AJNR Am J Neuroradiol 36:2147–2152CrossRefPubMedGoogle Scholar
  8. 8.
    Merchavy S, Luckman J, Guindy M et al (2016) 4D MRI for the Localization of Parathyroid Adenoma: A Novel Method in Evolution. Otolaryngol Head Neck Surg 154:446–448CrossRefPubMedGoogle Scholar
  9. 9.
    Mapelli P, Busnardo E, Magnani P et al (2012) Incidental finding of parathyroid adenoma with 11C-choline PET/CT. Clin Nucl Med 37:593–595CrossRefPubMedGoogle Scholar
  10. 10.
    Welle CL, Cullen EL, Peller PJ et al (2016) 11C-Choline PET/CT in Recurrent Prostate Cancer and Nonprostatic Neoplastic Processes. Radiographics 36:279–292CrossRefPubMedGoogle Scholar
  11. 11.
    Quak E, LHeureux S, Reznik Y et al (2013) F18-Choline, a novel PET tracer for parathyroid adenoma? J Clin Endocrinol Metab 98:3111–3112CrossRefPubMedGoogle Scholar
  12. 12.
    Hodolic M, Huchet V, Balogova S et al (2014) Incidental uptake of 18Ffluorocholine (FCH) in the head or in the neck of patients with prostate cancer. Radiol Oncol 48:228–234PubMedPubMedCentralGoogle Scholar
  13. 13.
    Cazaentre T, Clivaz F, Triponez F (2014) False-positive result in 18Ffluorocholine PET/CT due to incidental and ectopic parathyroid hyperplasia. Clin Nucl Med 39:328–330CrossRefGoogle Scholar
  14. 14.
    Wilhelm SM, Wang TS, Ruan DT et al (2016) The American association of endocrine surgeons guidelines for definitive management of primary hyperparathyroidism. JAMA Surg 151(10):959–968Google Scholar
  15. 15.
    Barber B, Moher C, Cote D et al (2016) Comparison of single photon emission CT (SPECT) with SPECT/CT imaging in preoperative localization of parathyroid adenomas: a cost-effectiveness analysis. Head Neck 38 Suppl 1:E2062–5Google Scholar
  16. 16.
    Frank SJ, Goldman-Yassen AE, Koenigsberg T, Libutti SK, Koenigsberg M (2017) Sensitivity of 3-dimensional sonography in preoperative evaluation of parathyroid glands in patients with primary hyperparathyroidism. J Ultrasound Med 36(9):1897–1904Google Scholar
  17. 17.
    Lalire P, Ly S, Dequelte S et al (2017) Incremental Value of 18F-Fluorocholine PET/CT in the Localization of Double Parathyroid Adenomas. Clin Nucl Med 42:218–220CrossRefPubMedGoogle Scholar
  18. 18.
    Huellner MW, Aberle S, Sah BR et al (2017) Visualization of Parathyroid Hyperplasia Using 18F-Fluorocholine PET/MR in a Patient With Secondary Hyperparathyroidism. Eur J Surg Oncol 43:133–137CrossRefGoogle Scholar
  19. 19.
    Vellani C, Hodoic M, Chytiris S et al (2017) Early and Delayed 18F-FCH PET/CT Imaging in Parathyroid Adenomas. Clin Nucl Med 42:143–144CrossRefPubMedGoogle Scholar
  20. 20.
    Michaud L, Balogova S, Burgess A et al (2015) A pilot comparison of 18F-fluorocholine PET/CT, ultrasonography and 123I/99mTc-sestaMIBI dual-phase dual-isotope scintigraphy in the preoperative localization of hyperfunctioning parathyroid glands in primary or secondary hyperparathyroidism: influence of thyroid anomalies. Medicine (Baltimore) 94(41):e1701Google Scholar
  21. 21.
    Michaud L, Burgess A, Huchet V et al (2014) Is 18F-fluorocholine-positron emission tomography/computerized tomography a new imaging tool for detecting hyperfunctioning parathyroid glands in primary or secondary hyperparathyroidism? J Clin Endocrinol Metab 99:4531–4536CrossRefPubMedGoogle Scholar
  22. 22.
    Kluijfhout WP, Vorselaars WM, Vriens MR et al (2015) Enabling minimal invasive parathyroidectomy for patients with primary hyperparathyroidism using Tc-99m-sestamibi SPECT-CT, ultrasound and first results of (18)F-fluorocholine PET-CT. Eur J Radiol 84:1745–1751CrossRefPubMedGoogle Scholar
  23. 23.
    Orevi M, Freedman N, Mishani E et al (2014) Localization of parathyroid adenoma by 11C-choline PET/CT: preliminary results. Clin Nucl Med 39:1033–1038CrossRefPubMedGoogle Scholar
  24. 24.
    Lezaic L, Rep S, Sever MJ et al (2014) 18F-Fluorocholine PET/CT for localization of hyperfunctioning parathyroid tissue in primary hyperparathyroidism: a pilot study. Eur J Nucl Med Mol Imaging 41:2083–2089CrossRefPubMedGoogle Scholar
  25. 25.
    Gayed IW, Kim EE, Broussard WF et al (2005) The value of 99mTc-sestamibi SPECT/CT over conventional SPECT in the evaluation of parathyroid adenomas or hyperplasia. J Nucl Med 46:248–252PubMedGoogle Scholar
  26. 26.
    Vaz A, Griffiths M (2011) Parathyroid imaging and localization using SPECT/CT: initial results. J Nucl Med Technol 39:195–200CrossRefPubMedGoogle Scholar
  27. 27.
    Lavely WC, Goetze S, Friedman KP et al (2007) Comparison of SPECT/CT, SPECT, and planar imaging with single- and dual-phase (99m)Tc-sestamibi parathyroid scintigraphy. J Nucl Med 48:1084–1089CrossRefPubMedGoogle Scholar
  28. 28.
    Greenspan BS, Dillehay G, Intenzo C et al (2012) SNM practice guideline for parathyroid scintigraphy 4.0. J Nucl Med Technol 40:111–118CrossRefPubMedGoogle Scholar
  29. 29.
    Giussani A, Janzen T, Uusijärvi-Lizana H et al (2012) A compartmental model for biokinetics and dosimetry of 18F-choline in prostate cancer patients. J Nucl Med 53:985–993CrossRefPubMedGoogle Scholar
  30. 30.
    van Raalte DH, Vlot MC, Zwijnenburg A et al (2015) F18-Choline PET/CT: a novel tool to localize parathyroid adenoma? Clin Endocrinol 82:910–912CrossRefGoogle Scholar

Copyright information

© European Society of Radiology 2018

Authors and Affiliations

  • G. F. Huber
    • 1
    Email author
  • M. Hüllner
    • 2
  • C. Schmid
    • 3
  • A. Brunner
    • 3
  • B. Sah
    • 2
    • 4
  • D. Vetter
    • 5
  • P. A. Kaufmann
    • 2
  • G. K. von Schulthess
    • 2
  1. 1.Department of Otorhinolaryngology, Head & Neck SurgeryUniversity Hospital ZurichZurichSwitzerland
  2. 2.Department of Nuclear MedicineUniversity Hospital ZurichZurichSwitzerland
  3. 3.Department of Endocrinology, DiabetologyUniversity Hospital ZurichZurichSwitzerland
  4. 4.Department of Diagnostic and Interventional RadiologyUniversity Hospital ZurichZurichSwitzerland
  5. 5.Department of General SurgeryUniversity Hospital ZurichZurichSwitzerland

Personalised recommendations